Xiaoyang Li

1.5k citations
29 papers · 1.2k indexed · 1 hit paper · h-index 12
Topics
Sarcoma Diagnosis and Treatment (6 papers)Berberine and alkaloids research (5 papers)Immunotherapy and Immune Responses (3 papers)

In The Last Decade

Xiaoyang Li

27 papers receiving 1.2k citations

Hit Papers

Oral berberine improves brain dopa/dopamine levels to ame...2021202620222024202150100150200

Peers

Xiaoyang Li
Comparison fields: 5 of 109
  • Molecular Biology 680
  • Pharmacology 409
  • Pharmacology 263
  • Immunology 131
  • Oncology 112
Replace Zheyu Zhang with:
Zheyu Zhang China
Haibo Cheng China
Junkai Yan China
Jing Ren China
Simona Pace Germany
Yuhua Li China
Zhengwei Zhang China
Huan Du China
Xiaoxiao Qi China
Xiaoyang Li relative to Zheyu Zhang China Zheyu Zhang's profile →
Citations per field
00.5×10×20×30×40×49×
Zheyu Zhang · 1×
Citations per year

Countries citing papers authored by Xiaoyang Li

Since Specialization
Citations

This map shows the geographic impact of Xiaoyang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyang Li more than expected).

Fields of papers citing papers by Xiaoyang Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyang Li. The network helps show where Xiaoyang Li may publish in the future.

Co-authorship network of co-authors of Xiaoyang Li

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyang Li. A scholar is included among the top collaborators of Xiaoyang Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyang Li. Xiaoyang Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 11
4 3
5 1
6 8
7 11
8 3
9 1
10 2
11 20
12 8
13 100
14
Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiotabreakdown →
240
15 160
16 6
17 8
18 14
19 243
20 60

About Xiaoyang Li

Xiaoyang Li is a scholar working on Pharmacology, Pharmacology and Cancer Research, having authored 29 papers that have together received 1.2k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (6 papers), Berberine and alkaloids research (5 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Pharmacology (263 citations), Biological Psychiatry (67 citations) and Pharmacology (409 citations). Xiaoyang Li has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Jia‐Wen Shou, Zhenxiong Zhao, Shengji Yu, Bao‐Ying Wen, Jian‐Dong Jiang, Yuan Lin, Chi‐Yu He, Qian Tong, Ru Feng and Jie Fu. Their work appears in journals such as Nano Letters, ACS Nano and Biomaterials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026